<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>GeneNews Limited (TSX:GEN) is a molecular diagnostics company, uniquely positioned to deliver on the promise of personalized medicine </plain></SENT>
<SENT sid="1" pm="."><plain>GeneNews has developed and patented the Sentinel Principle(®), an innovative approach to identify clinically actionable disease biomarkers from the blood transcriptome </plain></SENT>
<SENT sid="2" pm="."><plain>Novel biomarker panels have been identified to address unmet clinical needs in a broad spectrum of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, including those for <z:hpo ids='HP_0002664'>oncology</z:hpo>, cardiovascular, metabolic and neurological related disorders </plain></SENT>
<SENT sid="3" pm="."><plain>Currently available products and services from GeneNews are: ColonSentry™, the world's first blood-based molecular test for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and; the SentinelGX™ Pharmacogenomic and Companion Diagnostic BloodRNA™ services, established to effectively support pharmaceutical partners in their companion diagnostic, development efforts </plain></SENT>
</text></document>